Moderna's stock surged 14% on Friday following news of a National Institutes of Health initiative to fast-track cancer research starting in December, modeled on pandemic vaccine development efforts. The public-private partnership will focus on pancreatic, liver, colorectal, and pediatric cancers, potentially accelerating Moderna's mRNA-based cancer therapies like its co-developed melanoma treatment with Merck.